논문검색
Author Woo Young Kim, M.D.1Suk-Joon Chang, M.D.1Ki-Hong Chang, M.D.1Jong-Hyuck Yoon, M.D.1Jang Hee Kim, M.D.2Byoung-Gie Kim, M.D.3Duk-Soo Bae, M.D.3Hee-Sug Ryu, M.D.1
Place of duty Departments of 1Obstetrics and Gynecology,2Pathology, Ajou University Hospital,Suwon,3Department of Obstetrics and Gynecology,Samsung Medical Center, Sungkyunkwan University School ofMedicine, Seoul, Korea
Title Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases
Publicationinfo Cancer Res Treat 2009 Mar; 041(01): 24-28.
Key_word Stage, Mitotic count, Adjuvant therapy, Prognostic factor
Full-Text
Abstract PurposeThe aim of this study was to evaluate the clinicopathological characteristics of uterineleiomyosarcoma (LMS) and possible prognostic factors. Materials and MethodsThis study included 31 patients with histologically proven LMS at Samsung Medical Centerand Ajou University Hospital between 1994 and 2007. The medical records and availablehistological slides were reviewed retrospectively. ResultsThe median age was 46 years (range, 32∼63). The most common symptom was vaginalbleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III,seven patients with stage IV disease. The median follow up time was 29 months (range, 1∼94). The most common recurrence site was lung (5 case), followed by pelvis and upperabdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%.Early tumor stage and mitotic count were the prognostic factor in univariate analysis(p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated withprognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stagedisease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF)had a trend for disease recurrence in early stage LMS (p=0.0859). ConclusionMitotic count less than 15/HPF in early stage may be related with longer progression-freeinterval, but we could not reach the conclusion that adjuvant therapy in early stage LMS beeffective.
출판정보 대한암학회지 2009 Mar; 041(01): 24-28.